

C2


19. (Amended) The use of the synthetic derivative of [any one of] claim[s] 1[,2, 6, 9, 13 and 14] as a marker for a polyamine transporter, wherein said synthetic derivative comprises a detectable label having affinity for a polyamine transporter and wherein said use comprises the steps of labeling said synthetic derivative to provide a labeled synthetic derivative, binding said labeled synthetic derivative to a polyamine transporter, and employing said labeled synthetic derivative bound to a polyamine transporter as a marker for the detection of a polyamine transporter.

C3

21. (Amended) A pharmaceutical composition for treating disorders wherein control of polyamine transport is required, comprising a synthetic derivative according to [any one of] claim[s] 1 [to 15] in combination with an acceptable pharmaceutical carrier.

Applicants do not believe a fee is due in connection with filing this Preliminary Amendment; however, the Commissioner is authorized to charge any fees which may be required to Deposit Account No. 50-1212/10004430/01973.

Respectfully submitted,



Steven L. Highlander
Attorney for Applicants

FULBRIGHT & JAWORSKI
600 Congress Avenue
Suite 1900
Austin, Texas 78701
(512) 418-3000

Date: April 10, 2000